Medicines Patent Pool Announces Sub-Licensing Agreements


The Medicines Patent Pool today announced its first round of sub-licensing agreements with four generic manufacturers for the production and sale of a generic line of Bristol-Myers Squibb’s daclatasvir to 112 lower-to middle income countries.

The initial list of sub-licences for the production of daclatasvir includes Cipla, Hetero and Emcure, all generic manufacturers with which the MPP has already partnered with in producing generic HIV antiretrovirals.

Subscribe to get the latest news